You are here

Our science / Clinical Trials / Find a Trial / NCT00159666

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

Back to Search Print Save as PDF Bookmark Trial

NCT00159666

Last updated on May 12, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Post-Herpetic Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of PHN with pain present for at least three months after the healing of a
Herpes Zoster skin lesion.

- Subjects must have completed the Daily Pain Rating Scale in the electronic diary at
least 4 times during screening and have an average daily pain rating score of greater
than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of neurolytic or neurosurgical therapy for PHN.

- Presence of any severe pain associated with conditions other than PHN that may
confound the assessment or self-evaluation of the pain due to PHN.

NCT00159666
Pfizer
Completed
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Neuralgia
P4 (Pregabalin for Peripheral Posttraumatic Pain)
NCT00292188
All Genders
18+
Years
Multiple Sites
Diabetic Neuropathies, Neuralgia
Pregabalin Peripheral Neuropathic Pain Study
NCT00141219
All Genders
18+
Years
Multiple Sites
Post-Herpetic Neuralgia
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
NCT00159666
All Genders
18+
Years
Multiple Sites
Neuralgia
A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain
NCT00631943
All Genders
18+
Years
Multiple Sites
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo
The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Post-Herpetic Neuralgia
Drug: pregabalin
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
255
June 2006
Not Provided

Inclusion Criteria:

  • Diagnosis of PHN with pain present for at least three months after the healing of a Herpes Zoster skin lesion.
  • Subjects must have completed the Daily Pain Rating Scale in the electronic diary at least 4 times during screening and have an average daily pain rating score of greater than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).

Exclusion Criteria:

  • History of neurolytic or neurosurgical therapy for PHN.
  • Presence of any severe pain associated with conditions other than PHN that may confound the assessment or self-evaluation of the pain due to PHN.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   Italy,   Spain,   United Kingdom,   United States
 
 
NCT00159666
A0081004
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2006

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now